


Angstrom6

Chemical Properties

CAS No. :	220334-14-5
Formula:	C39H62N10O15
Molecular Weight:	910.97
Storage:	Keep away from moisture Powder: -20°C for 3 years In solvent: -80°C for 1 year <i>Actual storage temperature shall be subject to the COA.</i>



Biological Description

Description	Angstrom6 (A-6 peptide) is an 8 amino acid peptide derived from single chain urokinase fibrinogen activator (scuPA) that interferes with the uPA/uPAR cascade and abrogates the downstream effects. Angstrom6 has antitumor activity and inhibits tumor cell migration, invasion, and metastasis by binding to CD44 and modulating CD44-mediated cell signaling.
Targets(IC50)	PAI-1

Solubility Information

Solubility	DMSO: 50 mg/mL (54.89 mM), Sonication is recommended. H2O: 50 mg/mL (54.89 mM), Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (2.2 mM), Sonication is recommended. <i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i>

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	1.0977 mL	5.4887 mL	10.9773 mL
5 mM	0.2195 mL	1.0977 mL	2.1955 mL
10 mM	0.1098 mL	0.5489 mL	1.0977 mL
50 mM	0.022 mL	0.1098 mL	0.2195 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Ghamande SA, et al. A phase 2, randomized, double-blind, placebo-controlled trial of clinical activity and safety of subcutaneous A6 in women with asymptomatic CA125 progression after first-line chemotherapy of epithelial ovarian cancer. *Gynecol Oncol.* 2008 Oct;111(1):89-94.

Finlayson M. Modulation of CD44 Activity by A6-Peptide. *Front Immunol.* 2015 Mar 30;6:135.

Piotrowicz RS, et al. A6 peptide activates CD44 adhesive activity, induces FAK and MEK phosphorylation, and inhibits the migration and metastasis of CD44-expressing cells. *Mol Cancer Ther.* 2011 Nov;10(11):2072-82.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481